Introduced

Passed Senate

Passed House

Became law

Adjourned sine die. The bill was pending when the session ended, so it did not pass.

Last action · February 19, 2026

To Committee On Committees (S)

Introduced February 19, 2026

Senate

Adjourned Sine Die

2026 Regular Session

SB211

AN ACT relating to coverage for prescription drugs.

Create a new section of Subtitle 17A of KRS Chapter 304 to require health plans to include a generic drug or biosimilar on the plan's formulary under specified circumstances; define terms; establish cost-sharing requirements when a generic drug or biosimilar is required to be placed on the health plan's formulary; prohibit a health plan from imposing any prior authorization, step therapy, or other limitation on coverage for a generic drug or biosimilar required to be…

Drugs and Medicines Education, Higher Effective Dates, Delayed Health and Medical Services Insurance, Health Pharmacists State Employees

Read the full text Kentucky Legislature LegiScan

AI-generated. Always verify with primary sources

Plain-language summary

Beta

This bill would require health insurance plans in Kentucky to include generic drugs and biosimilars on their covered drug lists under certain conditions, and would ban insurers from making it harder to access those lower-cost alternatives compared to brand-name drugs. It also removes requirements like prior authorization or step therapy for these drugs when they qualify under the bill's rules. The law would apply to plans issued or renewed starting January 1, 2027. Who it may affect: Kentuckians with private health insurance, state employees, students and employees covered by state university health plans, and pharmacists.

Open official bill text (PDF)·Report a problem with the summary